- Home
- BCTX vs PASG Comparison
BCTX vs PASG Comparison
Compare BCTX & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BCTX | PASG |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | Canada | United States |
| Employees | N/A | 27 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.8M | 26.0M |
| IPO Year | 2025 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BCTX | PASG |
|---|---|---|
| Price | $4.10 | $6.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $40.00 | $24.80 |
| AVG Volume (30 Days) | ★ 134.9K | 32.0K |
| Earning Date | 03-10-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $380.95 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.61 | $0.28 |
| 52 Week High | $14.68 | $20.00 |
Technical Indicators
Market Signals| Indicator | BCTX | PASG |
|---|---|---|
| Relative Strength Index (RSI) | 45.11 | 38.68 |
| Support Level | $3.66 | N/A |
| Resistance Level | $4.51 | $8.55 |
| Average True Range (ATR) | 0.27 | 1.40 |
| MACD | 0.00 | 0.08 |
| Stochastic Oscillator | 20.83 | 0.54 |
Price Performance
Historical ComparisonAbout BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.
About PASG Passage Bio Inc.
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.